Skip to main content

This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

bioRxiv logoLink to bioRxiv
[Preprint]. 2023 Jul 4:2023.07.03.547507. [Version 1] doi: 10.1101/2023.07.03.547507

Deep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis

Jun Inamo, Joshua Keegan, Alec Griffith, Tusharkanti Ghosh, Alice Horisberger, Kaitlyn Howard, John Pulford, Ekaterina Murzin, Brandon Hancock, Anna Helena Jonsson, Jennifer Seifert, Marie L Feser, Jill M Norris, Ye Cao, William Apruzzese, S Louis Bridges, Vivian Bykerk, Susan Goodman, Laura Donlin, Gary S Firestein, Harris Perlman, Joan M Bathon, Laura B Hughes, Darren Tabechian, Andrew Filer, Costantino Pitzalis, Jennifer H Anolik, Larry Moreland, Joel M Guthridge, Judith A James, Michael B Brenner, Soumya Raychaudhuri, Jeffrey A Sparks; The Accelerating Medicines Partnership RA/SLE Network, V Michael Holers, Kevin D Deane, James A Lederer, Deepak A Rao, Fan Zhang
PMCID: PMC10349983  PMID: 37461737

Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disease with currently no universally highly effective prevention strategies. Identifying pathogenic immune phenotypes in ‘At-Risk’ populations prior to clinical disease onset is crucial to establishing effective prevention strategies. Here, we applied mass cytometry to deeply characterize the immunophenotypes in blood from At-Risk individuals identified through the presence of serum antibodies to citrullinated protein antigens (ACPA) and/or first-degree relative (FDR) status (n=52), as compared to established RA (n=67), and healthy controls (n=48). We identified significant cell expansions in At-Risk individuals compared with controls, including CCR2+CD4+ T cells, T peripheral helper (Tph) cells, type 1 T helper cells, and CXCR5+CD8+ T cells. We also found that CD15+ classical monocytes were specifically expanded in ACPA-negative FDRs, and an activated PAX5 low naïve B cell population was expanded in ACPA-positive FDRs. Further, we developed an “RA immunophenotype score” classification method based on the degree of enrichment of cell states relevant to established RA patients. This score significantly distinguished At-Risk individuals from controls. In all, we systematically identified activated lymphocyte phenotypes in At-Risk individuals, along with immunophenotypic differences among both ACPA+ and ACPA-FDR At-Risk subpopulations. Our classification model provides a promising approach for understanding RA pathogenesis with the goal to further improve prevention strategies and identify novel therapeutic targets.

Full Text Availability

The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.


Articles from bioRxiv are provided here courtesy of Cold Spring Harbor Laboratory Preprints

RESOURCES